tbuckley/cabot-search huggingface dataset:
Fractures and Joint Injuries
Authors: J Kajfes
Journal: BMJ (1943)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
Relationship Between Initiating Dose and Concentration of Rous Sarcoma Virus (Type O) in Tumors of Germfree Quail&lt;xref ref-type="fn" rid="FN2"&gt;2&lt;/xref&gt;
Authors: W R Bryan, M R Sacksteder, R D Schwartz, J P Kvedar, P K Vogt, J Warren
Journal: JNCI Journal of the National Cancer Institute (1971)

A correlation is shown between the amount of Rous sarcoma virus (type O) [RSV(O)] used to induce tumors and amount of infectious progeny virus recoverable from tumor tissue of germfree Japanese quail. The quail were also free of naturally occurring group-specific antigen of avian tumor virus. The results are in accord with the idea that the reproduction of infectious RSV(O) is dose dependent in certain cell types.
Outbreak of leptospirosis among canyoning participants, Martinique, 2011
Authors: P Hochedez, M Escher, H Decoussy, L Pasgrimaud, R Martinez, J Rosine, R Théodose, P Bourhy, M Picardeau, C Olive, M Ledrans, A Cabié
Journal: Eurosurveillance (2013)

Binary file ES_Abstracts_Final_ECDC.txt matches
THE DISCRIMINATION OF COLOUR
Authors: F. W. Edridge-Green
Journal: BMJ (1911)

In a paper on the relation of light perception to colour perception, and in previous writings, I have stated that if a portion of the spectrum be isolated, it will appear monochromatic, the length of the monochromatic region varying with the intensity and wave-length of the light and the colour perception of the observer. Most normal sighted persons make about eighteen such divisions in a bright spectrum. In a paper in the ‘Proceedings of the Royal Society,' Lord Rayleigh, whilst agreeing that the facts were as I stated in the conditions described by me, expressed the opinion that he could distinguish between the wavelengths included in a monochromatic division to the extent of discriminating between the colours of the two D lines. Lord Rayleigh kindly lent me the colour box with which he had made the experiments, and, on repeating them in the manner described by him, I arrived at similar results. I hope, however, to be able to show that the results obtained by Lord Rayleigh were due to the admixture of small quantities of white and coloured light and to certain physiological influences which had not been taken into consideration, and which prevented him from arriving at a correct interpretation of the colours.
Abstract A08: IGF1R as a key target in high risk, metastatic medulloblastoma
Authors: Matthew N. Svalina, Ken Kikuchi, Jinu Abraham, Sangeet Lal, Monika A. Davare, Jennifer L. Peckham, Yoon-Jae Cho, Melanie Jackson, Daniel J. Guillaume, Nathan R. Selden, Darell D. Bigner, Kellie J. Nazemi, Sarah C. Green, Christopher L. Corless, Sakir Gultekin, Brian P. Rubin, Randall Woltjer, Charles Keller
Journal: Cancer Research (2015)

Abstract The risk or presence of metastasis in childhood medulloblastoma represents a substantial cause of morbidity and mortality. Relatively little has been known about the molecular mechanisms of medulloblastoma dissemination throughout the cerebrospinal axis. To determine potential interventions that address both metastasis and tumor growth, we examined the expression of cytokines and growth factors in the CSF of metastatic medulloblastoma patients that were also present in the conditioned media of metastatic, MYC amplified medulloblastoma cell lines and/or cell culture models of the leptomeninges. The presence of IGF1, the IGF-sequestering protein Igfbp3, which can be cleaved by metal metalloproteases (MMP) and the serine protease tPA, and the presence of corresponding protease modulators TIMP1 and SerpinE1/PAI-1, led us to explore the bioactivity of IGF1 in medulloblastoma. IGF1 led not only to receptor phosphorylation but also increased migration and increased relative cell growth. A tumor cell viability screen of 60 clinically-related compounds prioritized IGF1R inhibitors. Our findings support a model whereby medulloblastoma tumor cells actively migrate, rather than arrive passively, to the leptomeningeal cell surface and provide a rationale for exploring IGF1R as a target for therapeutics in future clinical trials. Citation Format: Matthew N. Svalina, Ken Kikuchi, Jinu Abraham, Sangeet Lal, Monika A. Davare, Jennifer L. Peckham, Yoon-Jae Cho, Melanie Jackson, Daniel J. Guillaume, Nathan R. Selden, Darell D. Bigner, Kellie J. Nazemi, Sarah C. Green, Christopher L. Corless, Sakir Gultekin, Brian P. Rubin, Randall Woltjer, Charles Keller. IGF1R as a key target in high risk, metastatic medulloblastoma. [abstract]. In: Proceedings of the AACR Special Conference: Advances in Brain Cancer Research; May 27-30, 2015; Washington, DC. Philadelphia (PA): AACR; Cancer Res 2015;75(23 Suppl):Abstract nr A08.
Early to Dialyze
Authors: Glenn M. Chertow, Wolfgang C. Winkelmayer
Journal: JAMA (2016)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
Lactate infusions in obsessive-compulsive disorder
Authors: J M Gorman, M R Liebowitz, A J Fyer, D Dillon, S O Davies, J Stein, D F Klein
Journal: American Journal of Psychiatry (1985)

Panic attacks followed sodium lactate infusions in one of seven patients with obsessive-compulsive disorder and 26 of 48 patients with panic disorder or agoraphobia with panic attacks. This suggests that lactate-induced panic is specific to the latter groups.
Biologic Studies on the Development of DON Resistance in a Mast-Cell Neoplasm of the Mouse
Authors: Michael Potter
Journal: JNCI Journal of the National Cancer Institute (1959)

The ascitic form of the mast-cell neoplasm P815 and the glutamine antagonist DON (6-diazo-5-oxo-l-norleucine), a growth inhibitor of P815, were used as a biologic system for studying the development of DON resistance. Titration studies were performed in which varying doses of ascitic tumor cells (102 to 107) were inoculated into untreated and DON-treated mice. Mice inoculated with 105 or more cells and treated with DON developed growing populations while under treatment, but consistently outlived the untreated control mice by more than 100 percent of the average survival time of controls. Some DON-treated mice inoculated with 102 or 103 cells did, however, survive indefinitely. A number of isolations of tumor cells were made from treated mice inoculated with the various cell doses. Characterizing these isolations for sensitivity or resistance revealed the following: Some cell populations were resistant and remained so; others, while showing resistance, lost this characteristic during serial transfer in untreated mice, and some were near-sensitive. Reconstruction studies were done by mixing various numbers of sensitive and known-resistant cells. Through this technique it was possible to detect, on the basis of survival time, as few as 10 to 20 resistant cells. From these experiments it was concluded: (1) Some cells sensitive to DON may be destroyed during DON treatment, but others persist as sensitive cells. (2 Resistance to DON may develop in these cells and hence during contact with DON. (3) Some resistant populations that are not stable are mixed populations (sensitive and resistant) in which sensitive cells apparently have a selective advantage over resistant cells during transfer through untreated mice.
Humoral immune function in pediatric patients treated with autologous bone marrow transplantation for B cell non-Hodgkin's lymphoma. The influence of ex vivo marrow decontamination with anti-Y 29/55 monoclonal antibody and complement
Authors: C Baumgartner, A Morell, A Hirt, U Bucher, HK Forster, JE Doran, L Matter, G Brun del Re, HP Wagner
Journal: Blood (1988)
Association of nonsuppression of cortisol on the DST with primary polydipsia in chronic schizophrenia
Authors: M B Goldman, L Blake, R C Marks, D Hedeker, D J Luchins
Journal: American Journal of Psychiatry (1993)

Thirteen polydipsic and 40 nonpolydipsic chronic schizophrenic patients received the dexamethasone suppression test while stabilized on psychotropic medication regimens. Thirty-eight percent (N = 5) of those with polydipsia but only 5% (N = 2) of those without polydipsia were nonsuppressors of cortisol (i.e., had an abnormal response). It is suggested that hippocampal dysfunction could cause both polydipsia and cortisol dysregulation in these patients.
Depression, competence, and the right to refuse lifesaving medical treatment
Authors: M D Sullivan, S J Youngner
Journal: American Journal of Psychiatry (1994)

The authors explore the possibility that psychiatrists inappropriately extend their views on suicide by the medically well to refusal of lifesaving treatment by the seriously medically ill.The legal and bioethics literature on competence to refuse lifesaving treatment and the possible impact of depression on this refusal is reviewed.Over the past 20 years, the burden of proof concerning the mental competence of seriously medically ill patients who refuse lifesaving treatment has shifted to the persons who seek to override these refusals. However, in psychiatry a patient's desire to die is generally considered to be evidence of an impaired capacity to make decisions about lifesaving treatment. This contrast between ethical traditions is brought into clinical focus during the evaluation and treatment of medically ill patients with depression who refuse lifesaving treatment. The clinical evaluation of the effect of depression on a patient's capacity to make medical decisions is difficult for several reasons: 1) depression is easily seen as a "reasonable" response to serious medical illness, 2) depression produces more subtle distortions of decision making than delirium or psychosis (i.e., preserving the understanding of medical facts while impairing the appreciation of their personal importance), and 3) a diagnosis of major depression is neither necessary nor sufficient for determining that the patient's medical decision making is impaired.Depression can be diagnosed and treated in patients with serious medical illness. But after optimizing medical and psychiatric treatment and determining that the patient is competent to make medical decisions, it may be appropriate to honor the patient's desire to die.
Crack/cocaine abusers in the general hospital: assessment and initiation of care
Authors: M Galanter, S Egelko, G De Leon, C Rohrs, H Franco
Journal: American Journal of Psychiatry (1992)

Cocaine, either smoked (as "crack") or taken intranasally, is now a common cause of psychiatric illness. This study was designed to assess the impact of cocaine abuse on a general psychiatric service and an obstetrics service in an urban general hospital and to evaluate a program for engaging affected patients in addiction treatment.The charts of 300 general psychiatric patients (not admitted for addiction treatment) and 60 cocaine-abusing prenatal or postpartum patients were reviewed. A treatment referral program based on professionally directed peer leadership was established for patients with cocaine abuse. Results of evaluation and referral of 100 other cocaine-abusing psychiatric patients and the 60 prenatal or postpartum patients were then determined.Fully 64% (N = 191) of the 300 psychiatric patients were diagnosed as substance abusers; 38% (N = 113) of them abused cocaine. Almost one-third of these cocaine abusers had no axis I diagnosis other than substance abuse/dependence, and the majority were homeless. Urine samples were positive for cocaine in a majority of the obstetric patients studied. A majority of the psychiatric patients who were referred through the peer-led program enrolled in outpatient cocaine treatment--three times as many as in the chart review group. Most of the obstetric patients suitable for referral enrolled for treatment as well.Cocaine abuse may be responsible for a large portion of psychiatric admissions in urban public general hospitals. Cocaine abusers in psychiatric and obstetrics services are apparently responsive to a peer-oriented mode of referral into treatment.
The methylphenidate test for differentiating desipramine-responsive from nortriptyline-responsive depression
Authors: H C Sabelli, J Fawcett, J I Javaid, S Bagri
Journal: American Journal of Psychiatry (1983)

Monitoring tricyclic antidepressant concentrations in the plasma of 43 patients with major depressive disorders indicated that some responded to imipramine or desipramine but not to amitriptyline or nortriptyline, or vice versa, even though plasma levels were within therapeutic ranges. Mood elevation by methylphenidate predicted marked improvement from treatment with imipramine or desipramine but not with amitriptyline or nortriptyline. When methylphenidate failed to improve mood, patients responded to amitriptyline or nortriptyline but not to desipramine. These results suggest differential drug responses with different tricyclic antidepressants, the clinical utility of the methylphenidate test, and the heterogeneity of depressions. The authors question the mechanism of action of nortriptyline via blockade of norepinephrine reuptake.
Human RhDel is caused by a deletion of 1,013 bp between introns 8 and 9 including exon 9 of RHD gene.
Authors: Jan-Gowth Chang, Jyh-Chwan Wang, Tzu-Yao Yang, Kun-Wu Tsan, Mu-Ching Shih, Ching-Tien Peng, Chang-Hai Tsai
Journal: Blood (1998)
Diagnosis of nonpatients in the general community
Authors: F S Mendelsohn, G Egri, B P Dohrenwend
Journal: American Journal of Psychiatry (1978)

Using a sample of 116 subjects drawn from a large metropolitan area, the authors compared ratings of psychopathology from both structured and clinical interviews. Although the two types of interviews yielded similar findings when there was definite psychopathology or definite signs of health, for some subjects in the middle range between health and sickness, the two interviews did not yield similar findings. The authors suggest the need for a new typology to categorize nonpatients in the community who are in the middle range between frank psychiatric disorder and optimal mental health.
A new framework for the interpretation of IgE sensitization tests
Authors: G. Roberts, M. Ollert, R. Aalberse, M. Austin, A. Custovic, A. DunnGalvin, P. A. Eigenmann, F. Fassio, C. Grattan, P. Hellings, J. Hourihane, E. Knol, A. Muraro, N. Papadopoulos, A. F. Santos, S. Schnadt, K. Tzeli
Journal: Allergy (2016)

IgE sensitization tests, such as skin prick testing and serum-specific IgE, have been used to diagnose IgE-mediated clinical allergy for many years. Their prime drawback is that they detect sensitization which is only loosely related to clinical allergy. Many patients therefore require provocation tests to make a definitive diagnosis; these are often expensive and potentially associated with severe reactions. The likelihood of clinical allergy can be semi-quantified from an IgE sensitization test results. This relationship varies though according to the patients' age, ethnicity, nature of the putative allergic reaction and coexisting clinical diseases such as eczema. The likelihood of clinical allergy can be more precisely estimated from an IgE sensitization test result, by taking into account the patient's presenting features (pretest probability). The presence of each of these patient-specific factors may mean that a patient is more or less likely to have clinical allergy with a given test result (post-test probability). We present two approaches to include pretest probabilities in the interpretation of results. These approaches are currently limited by a lack of data to allow us to derive pretest probabilities for diverse setting, regions and allergens. Also, cofactors, such as exercise, may be necessary for exposure to an allergen to result in an allergic reaction in specific IgE-positive patients. The diagnosis of IgE-mediated allergy is now being aided by the introduction of allergen component testing which may identify clinically relevant sensitization. Other approaches are in development with basophil activation testing being closest to clinical application.
The Keap1–Nrf2–ARE Pathway As a Potential Preventive and Therapeutic Target: An Update
Authors: Meng‐Chen Lu, Jian‐Ai Ji, Zheng‐Yu Jiang, Qi‐Dong You
Journal: Medicinal Research Reviews (2016)

Abstract The Keap1–Nrf2–ARE ((Kelch‐like ECH‐Associating protein 1) nuclear factor erythroid 2 related factor 2‐antioxidant response element) pathway is one of the most important defense mechanisms against oxidative and/or electrophilic stresses, and it is closely associated with inflammatory diseases, including cancer, neurodegenerative diseases, cardiovascular diseases, and aging. In recent years, progress has been made in strategies aimed at modulating the Keap1–Nrf2–ARE pathway. The Nrf2 activator DMF (Dimethylfumarates) has been approved by the FDA as a new first‐line oral drug to treat patients with relapsing forms of multiple sclerosis, while a phase 3 study of another promising candidate, CDDO‐Me, was terminated for safety reasons. Directly inhibiting Keap1–Nrf2 protein–protein interactions as a novel Nrf2‐modulating strategy has many advantages over using electrophilic Nrf2 activators. The development of Keap1–Nrf2 protein–protein interaction inhibitors has become a topic of intense research, and potent inhibitors of this target have been identified. In addition, inhibiting Nrf2 activity has attracted an increasing amount of attention because it may provide an alternative cancer therapy. This review summarizes the molecular mechanisms and biological functions of the Keap1–Nrf2–ARE system. The main focus of this review is on recent progress in studies of agents that target the Keap1–Nrf2–ARE pathway and the therapeutic applications of such agents.
Natural history of ventricular septal defect.
Authors: A J Moss, B Siassi
Journal: BMJ (1971)

Natural History of Ventricular Septal Defect Isolated ventricular septal defect (V.S.D.) is the commonest single form of congenital heart disease at birth and accounts for 30% of all cardiac abnorrmalities at this time, or about 2 per 1,000 live births.' 2 This means that at least 1,700 babies
Abstract P2-05-17: ARGX-111 depletes MET-expressing circulating tumor cells via enhanced ADCC, resulting in inhibition of metastasis
Authors: V Morello, A Hultberg, N De Jonge, L Huyghe, V Hanssens, P Brouckaert, M Saunders, T Dreier, A Thibault, C Rolfo, P Aftimos, A Awada, P Michieli, H de Haard
Journal: Cancer Research (2016)

Abstract Several lines of experimental evidence suggest that Hepatocyte Growth Factor (HGF) and its receptor MET play an important role in breast cancer progression and drug resistance. To date, targeted MET inhibitors in clinical development have primarily shown cytostatic rather than cytotoxic effects. Development of a cytotoxic MET inhibitor would serve to complement standard breast cancer therapy, especially when administered in the adjuvant/neo-adjuvant setting. We have developed ARGX-111, a human antibody antagonist of MET function. ARGX-111 blocks both HGF-dependent and -independent signaling, down-regulates tumor cell surface expression of MET and kills MET-overexpressing cells by enhanced antibody-dependent cellular cytotoxicity (ADCC). ARGX-111 was shown to be more efficacious than an ADCC-inactive control antibody in both HGF-dependent and -independent tumor xenograft models. ADCC reporter assays confirmed the cytotoxic effects of ARGX-111 in patient-derived primary tumor specimens, including MET-expressing breast cancer stem-like cells. In an orthotopic mouse model of metastatic mammary carcinoma (MDA-MB-231), adjuvant or neo-adjuvant treatment with ARGX-111 was significantly more effective in depleting circulating tumor cells (CTCs) and suppressing the development of bone and lung metastases than the ADCC-inactive control. Taken together, these results provide a rationale for clinical investigation of ARGX-111 in the early breast cancer setting. An ongoing Phase 1 study (NCT02055066) is examining the effects of ARGX-111 on CTCs, alongside the assessment of its safety and efficacy. Citation Format: Morello V, Hultberg A, De Jonge N, Huyghe L, Hanssens V, Brouckaert P, Saunders M, Dreier T, Thibault A, Rolfo C, Aftimos P, Awada A, Michieli P, de Haard H. ARGX-111 depletes MET-expressing circulating tumor cells via enhanced ADCC, resulting in inhibition of metastasis. [abstract]. In: Proceedings of the Thirty-Eighth Annual CTRC-AACR San Antonio Breast Cancer Symposium: 2015 Dec 8-12; San Antonio, TX. Philadelphia (PA): AACR; Cancer Res 2016;76(4 Suppl):Abstract nr P2-05-17.